Fiscal Year Ending March 2026 Third Quarter Financial Summary [Japanese GAAP] (Consolidated)

Summary of Business Results

For the third quarter of the fiscal year ending March 2026, consolidated net sales increased 3.7% year-over-year to ¥2,911,667 million, driven by higher sales in the pharmaceutical wholesale business for ethical drugs as well as cosmetics, daily necessities, and OTC pharmaceutical wholesale businesses. On the other hand, operating income decreased 4.8% year-over-year to ¥43,183 million due to increased expenses in business investments, human resources, and logistics. Ordinary income rose 8.1% year-over-year to ¥61,313 million, supported by increased investment income, and net income attributable to owners of parent also grew 3.2% to ¥37,414 million.

Summary of Financial Position and Others

Total assets increased ¥194,387 million compared to the end of the previous fiscal year, reaching ¥2,019,371 million, primarily due to growth in current assets. Liabilities increased ¥168,406 million mainly due to higher notes payable and accounts payable. Net assets increased ¥25,980 million to ¥783,927 million. Share buybacks and cancellations were completed by the end of November 2025 and their impact has been reflected in the earnings forecast for the fiscal year ending March 2026. Corporate activities such as acquisition of shares in consolidated subsidiaries are also progressing.